Skip to content

ResMed RMD Allowance for Doubtful Accounts

Allowance for Doubtful Accounts at other companies

LivaNova logo
LivaNovaLIVN
Pulmonx Corporation logo
Pulmonx CorporationLUNG
Medtronic logo
MedtronicMDT
Abbott logo
AbbottABT
Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$1.4B+10.8%
Gross profit$891.0M+16.3%
Operating income$499.8M+17.3%
Net income$398.7M+9.2%
EPS (diluted)$2.74+10.5%

Balance sheet

See full
Cash & equivalents$1.7B+78.0%
Total debt$1.1B+29.8%
Total equity$6.5B+17.1%
Total assets$8.8B+16.1%

Cash flow

See full
Operating cash flow$554.1M-4.2%
CapEx$33.7M+61.8%
Free cash flow$520.5M-6.7%

Valuation

See full
Market cap$28.27B-19.1%
Enterprise value$27.71B-19.8%
P/E18.6×-6.3×
P/S5.1×-1.7×

Profitability

See full
Gross margin61.6%+2.8pp
Operating margin34.2%+2.1pp
Net margin27.4%+1.3pp
FCF margin31.7%+0.4pp

Returns & leverage

See full
Return on equity25.2%-0.6pp
Debt / equity0.2×0.0×
Current ratio-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's allowance for doubtful accounts.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ResMed's allowance for doubtful accounts?
ResMed (RMD) reported allowance for doubtful accounts of $29.47M in Q1 2026.
How has ResMed's allowance for doubtful accounts changed year-over-year?
ResMed's allowance for doubtful accounts increased by 48.7% year-over-year, from $19.83M to $29.47M.
What is the long-term trend for ResMed's allowance for doubtful accounts?
Over 4 years (2021 to 2025), ResMed's allowance for doubtful accounts has grown at a -8.6% compound annual growth rate (CAGR), from $32.14M to $22.42M.